This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.
You can find the current article at its original source at https://www.rt.com/russia/515754-russian-vaccines-uk-variant/
The article has changed 4 times. There is an RSS feed of changes available.
| Version 1 | Version 2 |
|---|---|
| Russian-made Sputnik V and EpiVacCorona vaccines are effective against UK variant of coronavirus – watchdog | Russian-made Sputnik V and EpiVacCorona vaccines are effective against UK variant of coronavirus – watchdog |
| (7 months later) | |
| Russia’s Sputnik V and EpiVacCorona vaccines have been proven to be effective against the UK variant of the coronavirus, a government agency has said. | Russia’s Sputnik V and EpiVacCorona vaccines have been proven to be effective against the UK variant of the coronavirus, a government agency has said. |
| Serum obtained from people who took the Sputnik V and EpiVacCorona vaccines and had antibodies to the novel coronavirus, demonstrated a “protective effect” against the UK variant, Russia’s consumer protection agency, Rospotrebnadzor, said in a statement to the media. | Serum obtained from people who took the Sputnik V and EpiVacCorona vaccines and had antibodies to the novel coronavirus, demonstrated a “protective effect” against the UK variant, Russia’s consumer protection agency, Rospotrebnadzor, said in a statement to the media. |
| It added that the vaccines have shown to be just as good against the British strain as they are against the ordinary SARS-CoV-2 virus, which causes Covid-19. | It added that the vaccines have shown to be just as good against the British strain as they are against the ordinary SARS-CoV-2 virus, which causes Covid-19. |
| The research was carried out by the Siberia-based Vector Institute, which developed EpiVacCorona. Russian President Vladimir Putin previously asked it to check whether the country’s vaccines are effective against the new strains of the virus. EpiVacCorona was cleared for mass production back in December, with the first batch of 45,000 doses released for sale to citizens in January. | The research was carried out by the Siberia-based Vector Institute, which developed EpiVacCorona. Russian President Vladimir Putin previously asked it to check whether the country’s vaccines are effective against the new strains of the virus. EpiVacCorona was cleared for mass production back in December, with the first batch of 45,000 doses released for sale to citizens in January. |
| Officials around the world are concerned that the emergence of new variants, which prompted additional restrictions in some countries, can potentially undermine the ongoing immunization campaigns. | Officials around the world are concerned that the emergence of new variants, which prompted additional restrictions in some countries, can potentially undermine the ongoing immunization campaigns. |
| Last August, Russia became the first country to register a Covid-19 vaccine – Sputnik V – with its national regulator. The vaccine, developed by the Moscow-based Gamaleya Institute, has since been authorized for emergency use in 26 countries, including Argentina, Serbia, Iran, Pakistan, Bahrain and the UAE. | Last August, Russia became the first country to register a Covid-19 vaccine – Sputnik V – with its national regulator. The vaccine, developed by the Moscow-based Gamaleya Institute, has since been authorized for emergency use in 26 countries, including Argentina, Serbia, Iran, Pakistan, Bahrain and the UAE. |
| The results of Sputnik V’s phase-three trial were confirmed by a review published in The Lancet medical journal earlier this month. The article authored by infectologists from the UK concluded that the trial results show “a consistent strong protective effect across all participant age groups.” | The results of Sputnik V’s phase-three trial were confirmed by a review published in The Lancet medical journal earlier this month. The article authored by infectologists from the UK concluded that the trial results show “a consistent strong protective effect across all participant age groups.” |
| Think your friends would be interested? Share this story! | Think your friends would be interested? Share this story! |
| Dear readers and commenters, | |
| We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system. | |
| Sorry for the inconvenience, and looking forward to your future comments, | |
| RT Team. |